1076198-37-2

Basic information

• Product Name: 6-MALEIMIDO-1-HEXANAL
• Synonyms: 6-MALEIMIDO-1-HEXANAL
• CAS NO: 1076198-37-2
• Molecular Formula: C10H13NO3
• Molecular Weight: 195.21512
• Product Categories: Nitric Oxide Reagents;Cross Linking Reagents;Maleimide Derivatives;Heterocycles;MTS & Sulfhydryl Active Reagents;Heterocycles, Maleimide Derivatives, MTS & Sulfhydryl Active Reagents
• Mol File: 1076198-37-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 6-MALEIMIDO-1-HEXANAL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-MALEIMIDO-1-HEXANAL(1076198-37-2)
• EPA Substance Registry System: 6-MALEIMIDO-1-HEXANAL(1076198-37-2)

Safety Data

• Hazardous Substances Data: 1076198-37-2(Hazardous Substances Data)

Usage

Chemical Properties

Light Yellow Oil

Uses

The alcohol is M138560

Upstream product

• 157503-18-9 1-(6-hydroxyhexyl)-1 H-pyrrole- 2,5-dione 
• 4048-33-3 6-amino-1-hexanol 

Relevant articles and documents

SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

ANTIBODY DRUG CONJUGATES

This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF

Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: Formula (I) and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

Antibody-Drug Conjugates, Compositions and Methods of Use

Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating can